Transient Changes in the Plasma of Astrocytic and Neuronal Injury Biomarkers in COVID-19 Patients without Neurological Syndromes
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24032715 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Matthew P Lennol und 12 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, 03550 San Juan de Alicante, Spain. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme 2, COVID-19. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”), CIBERNED (Instituto de Salud Carlos III, Spain), Instituto de Investigación Sanitaria y Biomédica de Alicante, Direcció General de Ciència I Investigació, Generalitat Valenciana.
Abstract (Originalsprache)
The levels of several glial and neuronal plasma biomarkers have been found to increase during the acute phase in COVID-19 patients with neurological symptoms. However, replications in patients with minor or non-neurological symptoms are needed to understand their potential as indicators of CNS injury or vulnerability. Plasma levels of glial fibrillary acidic protein (GFAP), neurofilament light chain protein (NfL), and total Tau (T-tau) were determined by Single molecule array (Simoa) immunoassays in 45 samples from COVID-19 patients in the acute phase of infection [moderate (n = 35), or severe (n = 10)] with minor or non-neurological symptoms; in 26 samples from fully recovered patients after ~2 months of clinical follow-up [moderate (n = 23), or severe (n = 3)]; and in 14 non-infected controls. Plasma levels of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), were also determined by Western blot. Patients with COVID-19 without substantial neurological symptoms had significantly higher plasma concentrations of GFAP, a marker of astrocytic activation/injury, and of NfL and T-tau, markers of axonal damage and neuronal degeneration, compared with controls. All these biomarkers were correlated in COVID-19 patients at the acute phase. Plasma GFAP, NfL and T-tau levels were all normalized after recovery. Recovery was also observed in the return to normal values of the quotient between the ACE2 fragment and circulating full-length species, following the change noticed in the acute phase of infection. None of these biomarkers displayed differences in plasma samples at the acute phase or recovery when the COVID-19 subjects were sub-grouped according to occurrence of minor symptoms at re-evaluation 3 months after the acute episode (so called post-COVID or “long COVID”), such as asthenia, myalgia/arthralgia, anosmia/ageusia, vision impairment, headache or memory loss. Our study demonstrated altered plasma GFAP, NfL and T-tau levels in COVID-19 patients without substantial neurological manifestation at the acute phase of the disease, providing a suitable indication of CNS vulnerability; but these biomarkers fail to predict the occurrence of delayed minor neurological symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, 03550 San Juan de Alicante, Spain.
- Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), 03550 San Juan de Alicante, Spain.
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 431 80 Mölndal, Sweden.
- Centre for Age-Related Medicine, Stavanger University Hospital, 4005 Stavanger, Norway.
- Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.
- Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, NIHR Biomedical Research Centre for Mental Health, London WC2R 2LS, UK.
ORCID-Profile: María-Salud García-Ayllón, Jose-Manuel Ramos-Rincon, Mariano Andrés, José-Manuel León-Ramírez, Esperanza Merino, Javier Sáez-Valero
Förderung
- Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”), CIBERNED (Instituto de Salud Carlos III, Spain)
- Instituto de Investigación Sanitaria y Biomédica de Alicante
- Direcció General de Ciència I Investigació, Generalitat Valenciana
- Swedish Research Council
- European Union’s Horizon Europe research and innovation programme
- Swedish State Support for Clinical Research
- Alzheimer Drug Discovery Foundation (ADDF), USA
- AD Strategic Fund and the Alzheimer’s Association
Zitieren
APA
Lennol, M. P., Ashton, N. J., Moreno-Pérez, O., García-Ayllón, M. S., Ramos-Rincon, J. M., Andrés, M., León-Ramírez, J. M., Boix, V., Gil, J., Blennow, K., Merino, E., Zetterberg, H., & Sáez-Valero, J. (2023). Transient Changes in the Plasma of Astrocytic and Neuronal Injury Biomarkers in COVID-19 Patients without Neurological Syndromes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032715
Vancouver
Lennol MP, Ashton NJ, Moreno-Pérez O, García-Ayllón MS, Ramos-Rincon JM, Andrés M, et al. Transient Changes in the Plasma of Astrocytic and Neuronal Injury Biomarkers in COVID-19 Patients without Neurological Syndromes. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24032715
BibTeX
@article{Lennol2023,
author = {Lennol, Matthew P and Ashton, Nicholas J and Moreno-Pérez, Oscar and García-Ayllón, María-Salud and Ramos-Rincon, Jose-Manuel and Andrés, Mariano and León-Ramírez, José-Manuel and Boix, Vicente and Gil, Joan and Blennow, Kaj and Merino, Esperanza and Zetterberg, Henrik and Sáez-Valero, Javier},
title = {Transient Changes in the Plasma of Astrocytic and Neuronal Injury Biomarkers in COVID-19 Patients without Neurological Syndromes},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24032715}
}
EUVIMED